Page last updated: 2024-09-05

sorafenib and Abnormalities, Autosome

sorafenib has been researched along with Abnormalities, Autosome in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fan, HK; Fan, J; Gao, Q; Ren, ZG; Xie, DY	1
Barlogie, B; Hoering, A; Hussein, MA; Mazzoni, S; Orlowski, RZ; Popplewell, LL; Sexton, R; Srkalovic, G; Trivedi, H; Zonder, JA	1
Chang, CJ; Chao, CH; Chen, CT; Hortobagyi, GN; Hsu, JM; Hung, MC; Woodward, WA; Xia, W; Xie, X; Yang, JY	1

Reviews

1 review(s) available for sorafenib and Abnormalities, Autosome

Article	Year
Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications. Clinical and translational gastroenterology, 2019, Volume: 10, Issue:2 Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chromosome Aberrations; Clone Cells; Diagnosis, Differential; Hepatectomy; Hepatitis B virus; High-Throughput Nucleotide Sequencing; Humans; Liver; Liver Neoplasms; Mutation; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Patient Selection; Precision Medicine; Sorafenib; Treatment Outcome; Tumor Suppressor Protein p53	2019

Article

Year

Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications.

Clinical and translational gastroenterology, 2019, Volume: 10, Issue:2

Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chromosome Aberrations; Clone Cells; Diagnosis, Differential; Hepatectomy; Hepatitis B virus; High-Throughput Nucleotide Sequencing; Humans; Liver; Liver Neoplasms; Mutation; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Patient Selection; Precision Medicine; Sorafenib; Treatment Outcome; Tumor Suppressor Protein p53

2019

Trials

1 trial(s) available for sorafenib and Abnormalities, Autosome

Article	Year
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer medicine, 2014, Volume: 3, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome	2014

Article

Year

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.

Cancer medicine, 2014, Volume: 3, Issue:5

Topics: Adult; Aged; Antineoplastic Agents; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2014

Other Studies

1 other study(ies) available for sorafenib and Abnormalities, Autosome

Article	Year
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer cell, 2011, Jan-18, Volume: 19, Issue:1 Topics: Animals; Benzenesulfonates; Benzimidazoles; beta Catenin; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Centrosome; Chromosome Aberrations; DNA Breaks, Double-Stranded; DNA Damage; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Models, Biological; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Polycomb Repressive Complex 2; Proto-Oncogene Proteins c-raf; Pyridines; Rad51 Recombinase; Signal Transduction; Sorafenib; Spheroids, Cellular; Transcription Factors; Transplantation, Heterologous; Xenograft Model Antitumor Assays	2011

Article

Year

EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.

Cancer cell, 2011, Jan-18, Volume: 19, Issue:1

Topics: Animals; Benzenesulfonates; Benzimidazoles; beta Catenin; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Centrosome; Chromosome Aberrations; DNA Breaks, Double-Stranded; DNA Damage; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Models, Biological; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Polycomb Repressive Complex 2; Proto-Oncogene Proteins c-raf; Pyridines; Rad51 Recombinase; Signal Transduction; Sorafenib; Spheroids, Cellular; Transcription Factors; Transplantation, Heterologous; Xenograft Model Antitumor Assays

2011